H. pylori eradication does not reduce gastric cancer incidence in a high-risk area of China

Evidence-based Healthcare Pub Date : 2004-08-01 DOI:10.1016/j.ehbc.2004.05.005

Bor-Shyang Sheu MD (Commentary Author), Xi-Zhang Lin MD (Commentary Author)

{"title":"H. pylori eradication does not reduce gastric cancer incidence in a high-risk area of China","authors":"Bor-Shyang Sheu MD (Commentary Author), Xi-Zhang Lin MD (Commentary Author)","doi":"10.1016/j.ehbc.2004.05.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Question</h3><p>Does treating <em>H. Pylori</em> reduce the incidence of gastric cancer?</p></div><div><h3>Study</h3><p>Randomised placebo-controlled trial.</p></div><div><h3>Main results</h3><p>At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, <em>n=</em>7; placebo: 1.35%, <em>n</em>=11; <em>p</em>=0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment <em>n</em>=0; placebo <em>n</em>=6; <em>p</em>=0.02) but there was no difference among people with precancerous lesions (<em>n</em>=7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk.</p></div><div><h3>Authors’ conclusions</h3><p>Incidence of gastric cancer was similar between <em>H. pylori</em> eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.</p></div>","PeriodicalId":100512,"journal":{"name":"Evidence-based Healthcare","volume":"8 4","pages":"Pages 218-220"},"PeriodicalIF":0.0000,"publicationDate":"2004-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ehbc.2004.05.005","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence-based Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1462941004000853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Question

Does treating H. Pylori reduce the incidence of gastric cancer?

Study

Randomised placebo-controlled trial.

Main results

At 7.5 years, incidence of gastric cancer was not significantly different between groups (treatment: 0.86%, n=7; placebo: 1.35%, n=11; p=0.33). In people without precancerous lesions at baseline, risk of gastric cancer was significantly lower for treatment compared with placebo (incidence of gastric cancer: treatment n=0; placebo n=6; p=0.02) but there was no difference among people with precancerous lesions (n=7 and 5, respectively). Smoking (hazard ratio [HR] 6.2, 95% CI 2.3 to 16.5) and older age (HR per 1 year 1.10, 95% CI 1.05 to 1.15) were independent predictors of gastric cancer risk.

Authors’ conclusions

Incidence of gastric cancer was similar between H. pylori eradication and placebo groups over 7.5 years of follow-up. However, it was significantly reduced in a subgroup of people without precancerous lesions at baseline.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

幽门螺杆菌根除并不能降低中国高风险地区胃癌的发病率

问题治疗幽门螺杆菌能降低癌症的发病率吗？研究随机安慰剂对照试验。主要结果7.5年时，各组癌症发生率无显著差异（治疗组：0.86%，n=7；安慰剂组：1.35%，n=11；p=0.33），与安慰剂相比，治疗癌症的风险显著降低（癌症的发病率：治疗n=0；安慰剂n=6；p=0.02），但癌前病变患者之间没有差异（分别为n=7和5）。吸烟（危险比[HR]6.2，95%CI 2.3-16.5）和年龄较大（每1年HR 1.10，95%CI 1.05-1.15）是癌症风险的独立预测因素。作者的结论在7.5年的随访中，根除幽门螺杆菌组和安慰剂组的癌症发病率相似。然而，在基线时没有癌前病变的亚组中，它显著降低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Evidence-based Healthcare

自引率

0.00%

发文量